Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma

Immunotherapy is now being routinely used in the management of many cancers. It is therefore vital that all clinicians are aware of the diverse array of cutaneous manifestations that can result from their use, which can vary from mild to life threatening.

Detalles Bibliográficos
Autores principales: Hanley, T, Papa, S, Saha, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170966/
https://www.ncbi.nlm.nih.gov/pubmed/30302265
http://dx.doi.org/10.1177/2054270418793029
_version_ 1783360714369400832
author Hanley, T
Papa, S
Saha, M
author_facet Hanley, T
Papa, S
Saha, M
author_sort Hanley, T
collection PubMed
description Immunotherapy is now being routinely used in the management of many cancers. It is therefore vital that all clinicians are aware of the diverse array of cutaneous manifestations that can result from their use, which can vary from mild to life threatening.
format Online
Article
Text
id pubmed-6170966
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61709662018-10-09 Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma Hanley, T Papa, S Saha, M JRSM Open Case Report Immunotherapy is now being routinely used in the management of many cancers. It is therefore vital that all clinicians are aware of the diverse array of cutaneous manifestations that can result from their use, which can vary from mild to life threatening. SAGE Publications 2018-10-03 /pmc/articles/PMC6170966/ /pubmed/30302265 http://dx.doi.org/10.1177/2054270418793029 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Hanley, T
Papa, S
Saha, M
Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title_full Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title_fullStr Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title_full_unstemmed Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title_short Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
title_sort bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170966/
https://www.ncbi.nlm.nih.gov/pubmed/30302265
http://dx.doi.org/10.1177/2054270418793029
work_keys_str_mv AT hanleyt bullouspemphigoidassociatedwithipilimumabtherapyforadvancedmetastaticmelanoma
AT papas bullouspemphigoidassociatedwithipilimumabtherapyforadvancedmetastaticmelanoma
AT saham bullouspemphigoidassociatedwithipilimumabtherapyforadvancedmetastaticmelanoma

Ejemplares similares